Evidence map›Paper›PMID 39057737›Full record

ArticleJournal of imaging2024

Development and Validation of Four Different Methods to Improve MRI-CEST Tumor pH Mapping in Presence of Fat.

Francesco Gammaraccio, Daisy Villano, Pietro Irrera, Annasofia A Anemone, Antonella Carella, Alessia Corrado, Dario Livio Longo

Abstract read
In one paragraph

Article in Journal of imaging, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Francesco GammaraccioDepartment of Molecular Biotechnology and Health Sciences, University of Turin, 10126 Torino, Italy.ORCID 0009-0007-9828-8506
Daisy VillanoDepartment of Molecular Biotechnology and Health Sciences, University of Turin, 10126 Torino, Italy.
Pietro IrreraInstitute of Biostructures and Bioimaging (IBB), National Research Council of Italy (CNR), 10126 Torino, Italy.
Annasofia A AnemoneDepartment of Molecular Biotechnology and Health Sciences, University of Turin, 10126 Torino, Italy.
Antonella CarellaInstitute of Biostructures and Bioimaging (IBB), National Research Council of Italy (CNR), 10126 Torino, Italy.
Alessia CorradoInstitute of Biostructures and Bioimaging (IBB), National Research Council of Italy (CNR), 10126 Torino, Italy.
Dario Livio LongoInstitute of Biostructures and Bioimaging (IBB), National Research Council of Italy (CNR), 10126 Torino, Italy.ORCID 0000-0002-6906-9925

Funding

Associazione Italiana Ricerca sul Cancro (AIRC) MFAG 20153Programma Operativo Nazionale Ricerca e Innovazione (PON) IMPARA - PIR01_00023
6 · The paper itself

Abstract

CEST-MRI is an emerging imaging technique suitable for various in vivo applications, including the quantification of tumor acidosis. Traditionally, CEST contrast is calculated by asymmetry analysis, but the presence of fat signals leads to wrong contrast quantification and hence to inaccurate pH measurements. In this study, we investigated four post-processing approaches to overcome fat signal influences and enable correct CEST contrast calculations and tumor pH measurements using iopamidol. The proposed methods involve replacing the Z-spectrum region affected by fat peaks by (i) using a linear interpolation of the fat frequencies, (ii) applying water pool Lorentzian fitting, (iii) considering only the positive part of the Z-spectrum, or (iv) calculating a correction factor for the ratiometric value. In vitro and in vivo studies demonstrated the possibility of using these approaches to calculate CEST contrast and then to measure tumor pH, even in the presence of moderate to high fat fraction values. However, only the method based on the water pool Lorentzian fitting produced highly accurate results in terms of pH measurement in tumor-bearing mice with low and high fat contents.

Indexed as

acidosischemical exchange saturation transfer (CEST)contrast agentfatiopamidolMRIpHpH responsivetumor

Identifiers

PMID39057737
PMCPMC11277679

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.